Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Rating of “Hold” by Analysts

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have been given a consensus recommendation of “Hold” by the nine analysts that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $20.50.

A number of brokerages have recently issued reports on KROS. Zacks Research raised Keros Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 27th. Wells Fargo & Company dropped their price target on shares of Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 4th. Wall Street Zen lowered shares of Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday. Leerink Partners reduced their price objective on shares of Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating for the company in a research note on Tuesday, August 4th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Keros Therapeutics in a research report on Tuesday, August 4th.

Keros Therapeutics Price Performance

KROS opened at $11.17 on Friday. The company has a market capitalization of $221.47 million, a price-to-earnings ratio of -3.02 and a beta of 1.01. The business has a 50 day moving average price of $10.83 and a two-hundred day moving average price of $11.29. Keros Therapeutics has a 1-year low of $9.69 and a 1-year high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Monday, August 3rd. The company reported ($1.45) earnings per share for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.40%. Equities analysts expect that Keros Therapeutics will post -5.27 EPS for the current fiscal year.

Insider Activity

In other news, insider Lorena Raquel Lerner sold 3,568 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $10.29, for a total transaction of $36,714.72. Following the completion of the transaction, the insider owned 27,559 shares of the company’s stock, valued at approximately $283,582.11. This represents a 11.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 5,893 shares of company stock worth $60,507. Insiders own 12.60% of the company’s stock.

Hedge Funds Weigh In On Keros Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. California State Teachers Retirement System lifted its position in shares of Keros Therapeutics by 72.6% in the 2nd quarter. California State Teachers Retirement System now owns 2,729 shares of the company’s stock worth $29,000 after acquiring an additional 1,148 shares during the period. Caitong International Asset Management Co. Ltd raised its stake in shares of Keros Therapeutics by 254.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock valued at $33,000 after purchasing an additional 1,166 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Keros Therapeutics by 149.2% in the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock valued at $42,000 after purchasing an additional 1,888 shares in the last quarter. Legal & General Group Plc bought a new position in Keros Therapeutics in the second quarter worth $90,000. Finally, PDT Partners LLC bought a new position in Keros Therapeutics in the second quarter worth $122,000. 71.56% of the stock is currently owned by institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.